Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
Clinical trial NCT04961619 · COMPLETED
Trial details
- NCT number
- NCT04961619
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-12-01
- Primary completion
- 2024-12-05
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.